Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target lowered by analysts at Scotiabank from $310.00 to $300.00. They now have a "sector outperform" rating on the stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $275.00 to $284.00. They now have an "equal weight" rating on the stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Alnylam: Q4 Earnings Snapshot [Yahoo! Finance]
https://seekingalpha.com/article/4758153-alnylam-waiting-for-regulatory-updates-in-march [Seeking Alpha]